39876-88-5

Basic information

• Product Name: 4-CHLORO-BENZO[4,5]FURO[3,2-D]PYRIMIDINE
• Synonyms: 4-chlorobenzofurano[3,2-d]pyrimidine;Benzofuro[3,2-d]pyrimidine, 4-chloro-;4-Chlorobenzofuro[3,2-d]pyrimidine
• CAS NO: 39876-88-5
• Molecular Formula: C₁₀H₅ClN₂O
• Molecular Weight: 204.61
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 39876-88-5.mol
• Article Data: 4

Chemical Properties

• Melting Point: 144.0 to 148.0 °C
• Boiling Point: 344.585 °C at 760 mmHg
• Flash Point: 162.199 °C
• Appearance: /
• Density: 1.474 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.728
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.21±0.40(Predicted)
• CAS DataBase Reference: 4-CHLORO-BENZO[4,5]FURO[3,2-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-BENZO[4,5]FURO[3,2-D]PYRIMIDINE(39876-88-5)
• EPA Substance Registry System: 4-CHLORO-BENZO[4,5]FURO[3,2-D]PYRIMIDINE(39876-88-5)

Safety Data

• Hazardous Substances Data: 39876-88-5(Hazardous Substances Data)

Usage

General Description

4-Chloro-benzo[4,5]furo[3,2-d]pyrimidine is a chemical compound belonging to the class of organic compounds called furopyrimidines. These are heterocyclic compounds featuring a furan ring fused to a pyrimidine ring. The exact biological functions or industrial uses of 4-chloro-benzo[4,5]furo[3,2-d]pyrimidine are not widely documented in literature, indicating that it might be primarily used for research purposes. The compound also includes a chlorine atom, which can influence its reactivity and potential applications. It should always be handled with proper safety measures due to possible hazards associated with its chemical properties.

InChI:InChI=1/C10H5ClN2O/c11-10-9-8(12-5-13-10)6-3-1-2-4-7(6)14-9/h1-5H

Upstream product

• 39786-36-2 4-oxo-3,4-dihydrobenzofuro<3,2-d>pyrimidine 
• 49615-99-8 (2-cyanophenoxy)acetonitrile 
• 68-12-2 N,N-dimethyl-formamide 
• 611-20-1 salicylonitrile 
• 57805-85-3 methyl 3-amino-2-benzofurancarboxylate 
• 34844-79-6 methyl 2-(2-cyanophenoxy)ethanoate 
• 54802-10-7 3-aminobenzofuran-2-carboxamide 

Downstream Products

• 65023-98-5 4-(2-chloro-phenylsulfanyl)-benzo[4,5]furo[3,2-d]pyrimidine 
• 65023-95-2 4-(3-methoxy-phenoxy)-benzo[4,5]furo[3,2-d]pyrimidine 
• 65023-91-8 4-p-tolyloxy-benzo[4,5]furo[3,2-d]pyrimidine 
• 65023-93-0 4-(3-chloro-phenoxy)-benzo[4,5]furo[3,2-d]pyrimidine 
• 65023-99-6 4-(3-chloro-phenylsulfanyl)-benzo[4,5]furo[3,2-d]pyrimidine 
• 65023-92-9 4-(2-chloro-phenoxy)-benzo[4,5]furo[3,2-d]pyrimidine 
• 65024-00-2 4-Hydrazinobenzofuro<3,2-d>pyrimidine 
• 39786-36-2 4-oxo-3,4-dihydrobenzofuro<3,2-d>pyrimidine 
• 65023-80-5 benzo[4,5]furo[3,2-d]pyrimidin-4-yl-cyclohexyl-amine 
• 65023-84-9 benzo[4,5]furo[3,2-d]pyrimidin-4-yl-(4-chloro-phenyl)-amine 
• 65023-90-7 4-m-tolyloxy-benzo[4,5]furo[3,2-d]pyrimidine 
• 65023-96-3 4-(4-methoxy-phenoxy)-benzo[4,5]furo[3,2-d]pyrimidine 
• 65023-81-6 N-phenylbenzofuro[3,2-d]pyrimidin-4-amine 
• 65023-83-8 benzo[4,5]furo[3,2-d]pyrimidin-4-yl-(3-chloro-phenyl)-amine 

Relevant articles and documents

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

Tyrosine kinase inhibitors. 16. 6,5,6-Tricyclic benzothieno[3,2-d]pyrimidines and pyrimido[5,4-b]- and -[4,5- b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase

Several elaborations of the fundamental anilinopyrimidine pharmacophore have been reported as potent and selective inhibitors of the epidermal growth factor receptor (EGFr) tyrosine kinase. This paper reports on a series of inhibitors whereby some 6,5-bicyclic heteroaromatic systems were fused through their C-2 and C-3 positions to this anilinopyrimidine pharmacophore. Although the resulting tricycles did not produce the enormous potency of some of the (5/6),6,6-bicyclic systems, the best of them had IC50s for the EGFr TK around 1 nM. Investigation of 4-position side chains in the indolopyrimidines confirmed that m-bromoaniline was an optimal substituent for potency. Investigation of substitution within the C-(benzo)ring of benzothienopyrimidines confirmed that introduction of an extra ring can change sharply the effects of substituents when compared to similar bicyclic nuclei, and only two substituents were found which even moderately enhanced inhibitory activity over the parent compound for this series.